Keywords
How to Cite
Abstract
Acute allergic conditions, notably anaphylactic shock, angioedema (Quincke's edema), and generalized acute urticaria, represent life-threatening emergencies precipitated by immunological (IgE-mediated) and non-immunological cascades. In clinical practice, disregarding the pharmacokinetic and pharmacodynamic profiles of administered drugs, alongside the unwarranted substitution of primary agents with secondary medications, frequently culminates in lethal outcomes. This study aims to clinically and pharmacologically evaluate the therapeutic efficacy, administration timing, and delivery routes of pharmaceutical agents (epinephrine, systemic glucocorticosteroids, H1-histamine receptor antagonists) deployed in the management of acute allergic reactions. Within a prospective and retrospective cohort design, the pharmacotherapeutic regimens of 220 patients admitted to emergency departments with acute allergic presentations were rigorously analyzed over an 18-month period. Multivariate logistic regression and survival models confirmed that failing to administer epinephrine (0.3-0.5 mg, intramuscularly)—the singular universal stimulator of alpha- and beta-adrenoreceptors in anaphylaxis pathogenesis—within the initial 5 minutes of symptom onset amplifies the risk of hemodynamic collapse by a factor of 4.8 (p < 0.001). The administration of antihistamines (chloropyramine) as first-line agents during shock objectively resulted in an additional 15-20% plunge in blood pressure, attributable to their alpha-adrenoblocking adverse effects. Given their genomic mechanism of action, systemic glucocorticosteroids (dexamethasone, prednisolone) demonstrated a therapeutic latency of 4-6 hours, proving critical solely in preventing biphasic (secondary) allergic reactions (reducing incidence from 18% to 4.2%). A rational clinico-pharmacological algorithm predicated on epinephrine pharmacokinetics (AUC = 0.912) provides a highly informative analytical substrate for radically ameliorating the quality of emergency medical care, minimizing cardiorenal complications, and curtailing patient mortality.
References
1. Katzung BG, Trevor AJ. Basic and Clinical Pharmacology. 15th ed. New York: McGraw Hill; 2021.
2. Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organization Journal. 2020;13(10):100472.
3. Muraro A, Roberts G, Worm M, et al. EAACI Food Allergy and Anaphylaxis Guidelines: managing patients with food allergy in the community. Allergy. 2014;69(8):1046-1057.
4. Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. Journal of Allergy and Clinical Immunology. 2020;145(4):1082-1123.
5. Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organization Journal. 2015;8(1):32.
6. Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis—a practice parameter update 2015. Annals of Allergy, Asthma & Immunology. 2015;115(5):341-384.
7. Campbell RL, Li JT, Nicklas RA, Sadosty AT. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Annals of Allergy, Asthma & Immunology. 2014;113(6):599-608.
8. Turner PJ, Jerschow E, Umasunthar T, et al. Fatal anaphylaxis: mortality rate and risk factors. Journal of Allergy and Clinical Immunology. Practice. 2017;5(5):1169-1178.
9. Macdougall IC, Bircher AJ, Eckardt KU, et al. Pathophysiology and management of anaphylaxis. Nature Reviews Disease Primers. 2021;7(1):1-16.
10. Zulfiqar AA, Andres E. Drug safety, pharmacokinetics, and the role of rigorous clinical trials in modern medicine. Journal of Clinical Pharmacology. 2021;61(3):289-301.
11. Tejedor-Alonso MA, Moro-Moro M, Múgica-García MV. Epidemiology of anaphylaxis: contributions from the last 10 years. Journal of Investigational Allergology and Clinical Immunology. 2015;25(3):163-175.
12. Wood RA, Camargo CA, Lieberman P, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. Journal of Allergy and Clinical Immunology. 2014;133(2):461-467.
13. Kemp SF, Lockey RF, Simons FE. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy. 2008;63(8):1061-1070.
14. Choo KJ, Simons E, Sheikh A. Glucocorticoids for the treatment of anaphylaxis. Cochrane Database of Systematic Reviews. 2012;4:CD007596.
15. Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis with and without shock. Cochrane Database of Systematic Reviews. 2007;1:CD006160.